Walmsley 2005.

Methods	CTN 164 trial N=134 Randomized Open label fup: 60 weeks w/o: reported
Participants	Eligibilty :‐ VL>1,000 cop/ml 2 ART remaining in salvage regimen, Baseline CD4 343 cells/mm3 Baseline VL 3.9 log copies/ml,. Baseline ART: PI + NRTI + NNRTI
Interventions	12 wks STI
Outcomes	CD4 decline: 132 cells/mm3; VL increase: 2.7 log copies/ml,
Notes	Genotypic shift predicted by nadir CD4;
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate